stoxline Quote Chart Rank Option Currency Glossary
Advaxis, Inc. (ADXS)
0.2501  -0.015 (-5.62%)    05-30 12:53
Open: 0.2
High: 0.26
Volume: 2,457
Pre. Close: 0.265
Low: 0.2
Market Cap: 11(M)
Technical analysis
2023-05-19 4:34:34 PM
Short term     
Mid term     
Targets 6-month :  1.26 1-year :  1.57
Resists First :  1.08 Second :  1.35
Pivot price 0.91
Supports First :  0.64 Second :  0.54
MAs MA(5) :  0.79 MA(20) :  0.98
MA(100) :  1.49 MA(250) :  2.27
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  15.2 D(3) :  20
RSI RSI(14): 34.6
52-week High :  7.19 Low :  0.05
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ADXS ] has closed above bottom band by 16.8%. Bollinger Bands are 24.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.85 - 0.86 0.86 - 0.86
Low: 0.68 - 0.69 0.69 - 0.69
Close: 0.71 - 0.72 0.72 - 0.73
Company Description

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

Headline News

Fri, 20 Jan 2023
Advaxis completes merger to become Ayala Pharmaceuticals - NJBIZ

Thu, 19 Jan 2023
Advaxis and Ayala Pharmaceuticals Complete Merger - GlobeNewswire

Thu, 20 Oct 2022
Advaxis enters merger deal with biotech firm Ayala - Pharmaceutical Technology

Wed, 19 Oct 2022
Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement - GlobeNewswire

Wed, 19 Oct 2022
Ayala Pharmaceuticals And Advaxis To Merge - Contract Pharma

Wed, 29 Jun 2022
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 5 (M)
Held by Insiders 1.49e+007 (%)
Held by Institutions 0 (%)
Shares Short 45 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.734e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 419.5 %
Return on Equity (ttm) -95.9 %
Qtrly Rev. Growth 692000 %
Gross Profit (p.s.) -42.92
Sales Per Share -81.34
EBITDA (p.s.) 0
Qtrly Earnings Growth -7.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -35 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow -0
Stock Dividends
Dividend 0
Forward Dividend 39890
Dividend Yield 0%
Dividend Pay Date 2019-03-28
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android